Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene + Venetoclax + Azacitidine in RARA-positive AML (SELECT-AML-1)
2024-510939-21-00Phase 2Completed
- Sponsor
- Syros Pharmaceuticals
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tamibarotene in acute myeloid leukemia (AML) (3 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Part 1 safety and Part 2 CR/CRi rate. Started Apr 2024; status: completed.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-510939-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510939-21-00.